AtaGenix's BEVS platform (Sf9/Sf21/Hi5) delivers properly folded, glycosylated recombinant proteins from milligram to gram scale. Four peer-reviewed publications showcase BEVS-produced reagents in oncology (Nat Commun, POLD1-MYC), tumor immunology (Biomed Pharmacother, PADI4 mAb), neuroscience (Nat Commun, PCIF1-MTase), and gynecological oncology (AJCR, ENO1 mAb). ISO 9001 & ISO 13485 certified.

AtaGenix's 3H E. coli expression platform (>95% success rate) delivers publication-grade recombinant proteins from mg to gram scale. Optimized vectors (pET/pGEX), specialized strains (T7E, C41, Arctic), and full QC (purity ≥85%, endotoxin <0.1 EU/mL). Three peer-reviewed case studies — all in Nature Communications — showcase E. coli-expressed reagents for rice genetics (SDR3.1), Bt resistance (FTZ-F1), and cyanobacterial stress tolerance (shikimate kinase).

AtaGenix's mammalian expression platform (HEK293/CHO-S transient, CHO-K1/DG44 stable) has delivered 5,000+ projects with 200+ stable cell lines. Four peer-reviewed publications showcase mammalian-expressed reagents: OMV tumor vaccine (Adv Mater IF 27.4), SARS-CoV-2 nanovaccine (Nat Commun IF 14.7), EAE neuroinflammation (Immunity IF 25.5), and PND complement inhibition (Mol Psychiatry IF 9.6). Class 100,000 cleanroom, endotoxin <0.1 EU/mL, ISO certified.

Using high-purity recombinant mouse MOG protein from AtaGenix, researchers established an EAE model and revealed how meningeal B cells drive MS relapse via MHC II-mediated antigen presentation, GM-CSF–dependent neutrophil recruitment, and endothelial activation. Local intracisternal anti-CD20 selectively depleted brain-resident B cells and reduced relapse severity. Published in Immunity (IF: 25.5). DOI: 10.1016/j.immuni.2025.06.016.

Patatin is a potato glycoprotein with emulsifying and antioxidant properties but limited by low expression and short-chain bias. With AtaGenix support, recombinant Patatin was expressed in Pichia pastoris (121 mg/L). The D286A mutant showed 3.2-fold enhanced activity toward long-chain pNP-C16, improved thermal stability, and maintained overall fold — demonstrating the first rational shift of Patatin's substrate preference toward industrial applications in functional lipids and green biocatalysis.

AtaGenix provides mammalian cell protein expression services (HEK293/CHO-S transient, CHO-K1/DG44 stable) for basic research, drug development, and diagnostic reagent production. 5,000+ projects delivered with native glycosylation, endotoxin <0.1 EU/mL, scalable from mL to 200 L+. ISO 9001 & ISO 13485 certified.

This study identifies USP8 as the key deubiquitinase regulating MDA5 homeostasis and reveals the AKT-USP8-MDA5 axis. AKT phosphorylates USP8 at Ser718, enhancing its activity and stabilizing MDA5 to promote type I interferon signaling. Targeting this axis offers a potential therapeutic strategy for MDA5-associated autoimmune diseases.

Intrahepatic cholangiocarcinoma (ICC) has poor prognosis due to chemo-immunotherapy (CIT) resistance, especially in AKT-hyperactivated cases. Published in Cancer Communications (2025), this study identified the pAKT-pPCK1-pLDHA-SPRINGlac axis as a key resistance driver. AtaGenix’s phospho-specific antibodies enabled core detection, and simvastatin reversed resistance by targeting the axis, with pAKT-pPCK1 as a prognostic biomarker.

This study identifies the PAD1-AKT2/R202 citrullination-CEBPβ axis as a key regulator of ovarian cancer stem cell (OCSC) properties and cisplatin resistance. Using an AtaGenix-customized Cit202 antibody, it demonstrates that PAD1-mediated citrullination activates AKT2, promoting stemness and resistance, which can be targeted with PAD1 inhibitor combined with cisplatin.